Activity of cathepsin D and α1-antitrypsin in the blood serum of patients with mammary carcinoma

Experimental Oncology

Volumn 27, Issue 3, 2005, Pages 233-237

  Wozniak, A ^a   Mila Kierzenkowska, C ^a   Schachtschabel, D O ^c   Wozniak, B ^a   Rozwodowska, M ^a   Drewa, T ^a   Drewa, S ^b   Sir, J ^d   Sir, I ^d   Maciak, R ^a   Krzyzynska Malinowska, E ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d Regional Oncology Centre Bydgoszcz   (Poland)

Author keywords

Breast tumor; Lysosomal enzymes; Protease inhibitors

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; CATHEPSIN D;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BREAST CARCINOMA; CANCER SIZE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PROTEIN ANALYSIS; PROTEIN DETERMINATION;

ADULT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN; BREAST NEOPLASMS; CATHEPSIN D; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS;

EID: 27744463644     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Bala G, Drewa G, Czerwionka-Szaflarska M, Wojciechowski M. Activity of arylsulphatase, cathepsin D and acid phosphatase in blood serum of children with gastritis and duodenitis - preliminary studies. Med Sci Monit 1998; 4: 430-5.
2. Barbi GP, Margallo E, Margiocco M, Paganuzzi M, Marroni P, Costanzi B, Gatteschi B, Tanara G, Spina B, Nicolo G. Evaluation of cathepsin D as prognostic predictor in breast cancer. Oncology 1994; 51: 329-33.
3. Bauman SJ, Church FC. Enhancement of heparin cofactor II anticoagulant activity. J Biol Chem 1999; 274: 4556-65.
4. Benraad JT, Geurts-Moespot A, Sala M, Piffanelli A, Ross A, Foekens IA. Quality control of cathepsin D measurement by the EORTC Receptor Study Group. Eur J Cancer 1992; 28: 72-9.
5. Berdowska J, Siewinski M, Zarzycki-Reich A, Jarmulowicz J, Noga L. Activity of cysteine protease inhibitors in human brain tumors. Med Sci Monit 2001; 7: 675-9.
6. Brouillet JP, Theillet C, Maudelonde T, Defrenne A, Simoini-Lafontaine J, Sertour J, Pujol H, Jeanteur P, Rochefort H. Cathepsin D assay in primary breast cancer and lymph nodes: relationships with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer 1990; 126: 437-41.
7. Capony F, Rougeot CI, Montcourrier P, Cavailles V, Salazar G, Rochefort H. Increased secretion, altered processing and glycosylation of pro-cathepsin D in human mammary cancer cells. Cancer Res 1989; 49: 3904-9.
8. Colowick SP, Kaplan NC. Methods in enzymology Vol. 2. New York: Academic Press, 1955.
9. Crombach G, Ingenhorst A, Gohring UJ, Snarl A. Cathepsin D concentrations in the cytosol of benign and malignant tumors of the breast and the female genital tract. Tumor Diagn Ther 1992; 13: 14-8.
10. Curran S, Murray GJ. Matrix metalloproteinase in tumor invasion and metastasis. J Pathol 1999; 189: 300-8.
11. Dati C, Antoniotti S, Taverna D, Perroteau I, De Bortoli M. Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990; 5: 1001-6.
12. Deussing J, Roth W, Saftig P, Peters C, Ploegh HL, Villadangos JA. Cathepsin B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc Natl Acad Sci USA 1998; 95: 4516-21.
13. Di Micco P, D'Uva M. To understand the two way clinical association between cancer and thrombophilia. Exp Oncol 2003; 25: 243-4.
14. Donati MB. Cancer metastasis: a model of cell-protease and cell-cell interactions. Haemostasis 2001; 31: 52-4.
15. Drewa T, Olszewska D, Makarewicz R, Drewa J, Wozniak A, Kowalke K. The significance of cathepsins B and D and their inhibitors in cancer diseases. Pol Merk Lek 2001; 11: 88-90.
16. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996; 2: 613-8.
17. Edwards DR, Murphy G. Cancer. Proteases - invasion and more. Nature 1998; 394: 527-8.
18. Falanga A. Tumor cell prothrombotic properties. Haemostasis 2001; 31: 1-4.
19. Garcia-Orad A, Arizti P, Duran L, Urcelay B, De Pancorbo MM. Alfa-1-antitrypsin phenotypes among breast cancer patients in the Basque population. Hum Hered 1994; 44: 203-8.
20. Kennett CN, Cox SW, Eley BM. Ultrastructural localization of cathepsin B in gingival tissue from chronic periodontitis patients. Histochem J 1997; 29: 727-34.
21. Konnova LA, Konnov BA, Melnikov LA, Zargarova OP. Antiprotease activity of the blood serum of patients with the disseminated form of breast cancer before and after combined treatment. Vopr Onkol 1983; 29: 7-9.
22. Kreienberg R, Koehler P, Kasemeyer R, Melchert F. Clinical utility of different tumor markers in breast cancer and gynecological malignancies. Cancer Detect Prev 1983; 61: 221-5.
23. Lamoureux G, Mandeville R, Poisson R, Legault-Poisson S, Jolicoeur R. Biologic markers and breast cancer: a multiparametric study. Increased serum protein levels. Cancer 1982; 49: 502-12.
24. Losch A, Tempfer C, Kohlberger P, Joura EA, Denk M, Zajic B, Breitenecker G, Kainz C. Prognostic value of cathepsin D expression and association with histomorphological subtypes in breast cancer. Brit J Cancer 1998; 78: 205-9.
25. Makarewicz R, Drewa G. A possible application of cathepsin B activity determination for estimating the spread of the cervix uteri carcinoma. Acta Biochim Pol 1996; 43: 521-4.
26. Maudelonde T, Martinez P, Brouillet JP, Laffargue F, Pages A, Rochefort H. Cathepsin D in human endometrium: induction by progesterone and potential and value as a tumor marker. J Clin Endocr Metab 1990; 70: 115-21.
27. Olszewska D, Drewa T, Makarewicz R, Drewa J, Wozniak A, Maciak R. The significance of cathepsin B and D in the physiological and pathological processes. Pol Merk Lek 2001; 55: 65-70.
28. Pujol P, Maudelonde T, Daures JP, Rouanet P, Brouillet JP, Pujol H, Rochefort H. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer 1993; 71: 2006-12.
29. Rochefort H, Capony F, Garcia M. Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metast Rev 1990; 9: 321-31.
30. Rochefort H. Biological and clinical significance of cathepsin D in breast cancer. Acta Oncol 1992; 31: 125-30.
31. Szczeklik E. Enzymologia kliniczna. Warszawa: PZWL, 1974. 389 pp.
32. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P, Janicke F, Graeff H. Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human breast cancer. Clin Cancer Res 1995; 1: 741-6.
33. Winstanley JH, Leinster SJ, Cooke TG, Westley BR, Platt-Higgins AM, Rudland PS. Prognostic significance of cathepsin-D in patients with breast cancer. Brit J Cancer 1993; 67: 767-72.